|
Public Policy
Contact your Congressperson
 Senate
House of Representatives
Major Changes to NIH Applications. Be Prepared!
Dear NIH principal investigators, signing officials, and applicants,
Are you planning to submit an NIH grant application? If so, please note that all applications intended for due dates on or after January 25, 2010* require the use of new forms and instructions. Major changes include:
- Restructured forms to align with review criteria
- Significantly shorter page limits
These changes apply to all competing applications, so whether you are submitting a new, renewal, resubmission or revision, you must take action now to ensure a successful submission!
- Return to the updated funding opportunity announcement or reissued parent announcement to download the new application package and instructions.
- FOAs are in the process of being updated. See timeline for more information.
- Be sure to choose the correct forms. Applications intended for due dates on or after January 25 require new forms.
- For Electronic SF 424 (R&R): ADOBE-FORMS-B
- For Paper PHS 398: Revision date “June 2009”
- Read the updated FOA and new application instructions carefully
For more details the Enhancing Peer Review Web site which has a page dedicated to the upcoming application changes, as well as a number of additional resources including:
Sincerely,
NIH Office of Extramural Research
Division of Communications and Outreach
* Applicants eligible for continuous submission who are submitting R01, R21, and R34 AIDS applications should use the old SF 424 (R&R) ADOBE-FORMS-A on or before February 7, 2010 and the new SF 424 (R&R) ADOBE-FORMS-B thereafter. Non-AIDS applications from applicants eligible for continuous submission need to us ADOBE-FORMS-A on or before January 24, and the ADOBE-FORMS-B on or after January 25, 2010.
Receive monthy updates on NIH grant policies and activities through the NIH Extramural Nexus.
Back To Top
Francis Collins, M.D., Ph.D. Confirmed as the 16th Director of the National Institutes of Health (NIH)
The AFMR is pleased to announce that Francis Collins, M.D., Ph.D. has been confirmed as the 16th director of the National Institutes of Health (NIH). Dr. Collins has been a member of the AFMR since 1990 and his contributions to the fields of science and medicine have been remarkable. The AFMR is extremely proud to have him as a member.
Read Dr. Collins' article about New Cancer Treatments
View more about Dr. Collins' appointment
Back To Top
The NIH Clinical Collection (NCC), a plated array of approximately 450 clinically tested compounds, is now available for distribution through www.nihclinicalcollection.com. There is a cost recovery charge of $805.00 for the collection.
Similar collections of FDA approved drugs have proven to be rich sources of undiscovered bioactivity and therapeutic potential. The clinically tested compounds in the NCC are highly drug-like with known safety profiles. These compounds can provide excellent starting points for medicinal chemistry optimization and, for high-affinity targets, may even be appropriate for direct human use in new disease areas. The compounds come as a ready-to-screen kit with the following features:
Format: The collection contains approximately 450 compounds arrayed in six 96-well plates. Compounds are supplied as 50ul of a 10mM solution in 100% DMSO.
Selection criteria: The NCC consists almost entirely of drugs that have been in phase I-III clinical trials and have not been represented in other available collections. These compounds also have favorable attributes for inclusion in a screening collection, such as purity, solubility and commercial availability for re-supply.
Drug-likeness: By definition, compounds that have been tested in human clinical trials have highly developed properties of drug-likeness, such as bioavailability and stability. Having been used in humans, most of these compounds also have well-characterized safety profiles.
Extensive Bioactivity Profiles: The NCC compounds are part of the screening library for the NIH Roadmap Molecular Libraries Screening Centers Network (MLSCN). Thus, extensive bioactivity data on these compounds from dozens of high throughput screens will be publicly available through PubChem. Through ongoing screening within and outside the MLSCN, the body of knowledge about these compounds will be continually expanding.
Resupply: All of the compounds in the NCC are commercially available for re-supply. Sources of compounds for the NCC are listed in the compound database.
The NCC was assembled by the National Institutes of Health through the Molecular Libraries Roadmap Initiative as part of its mission to enable the use of compound screens in biomedical research.
The NIH Roadmap for Medical Research is a series of far-reaching initiatives designed to transform the nation’s medical research capabilities and speed the movement of research discoveries from the bench to the bedside. It provides a framework of the priorities the NIH must address in order to optimize its entire research portfolio and lays out a vision for a more efficient and productive system of medical research. For more information about the NIH Roadmap, please visit the Web site at http://nihroadmap.nih.gov.
The National Institutes of Health (NIH) — The Nation's Medical Research Agency — is comprised of 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
Back To Top
The objective of the Mentored Clinical Scientist Research Career Development Award (K08) is to continue the long standing NIH support of didactic study and mentored research for individuals with clinical doctoral degrees. This award provides support and “protected time” for an intensive, supervised research career development experience in the fields of biomedical or behavioral research, including translational research. For the purpose of this award, translational research is defined as application of basic research discoveries toward the diagnosis, management, and prevention of disease.
An award is for a period of 3 to 5 years and provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds. Candidates for K08 award must have a clinical doctoral degree. Applications must contain a career development plan as well as a research plan. The participating NIH Institutes and Centers may have distinctive guidelines, requirements, and funding amounts for this announcement in order to accommodate the career needs of researchers working in fields related to their specific research missions.
For more information, please go to: http://grants.nih.gov/grants/guide/pa-files/PA-06-512.html#SectionI
Back To Top
NCRR News
The National Center for Research Offers Clinical and Translational Science Awards
Back To Top
> Browse Archives
|
